Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person:  The amounts reported in boxes 6, 8, and 9 represent 43,574 shares of common stock, no par value ("Common Stock"), of Korsana Biosciences, Inc. (formerly known as Cyclerion Therapeutics, Inc.) (the "Issuer") owned directly by private investment funds managed by ADAR1 Capital Management, LLC. Such securities may be deemed to be indirectly beneficially owned by ADAR1 Capital Management, LLC. The percentage in box 11 is based on 45,541,358 shares of Common Stock outstanding as of September 30, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2026, filed with the Securities and Exchange Commission on November 5, 2026, after giving effect to the 1-for-7 reverse stock split and the merger effected on September 8, 2026, as reported in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 11, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person:  The amounts reported in boxes 6, 8, and 9 represent 43,574 shares of common stock, no par value ("Common Stock"), of Korsana Biosciences, Inc. (formerly known as Cyclerion Therapeutics, Inc.) (the "Issuer") owned directly by private investment funds managed by ADAR1 Capital Management, LLC. Such securities may be deemed to be indirectly beneficially owned by Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC. The percentage in box 11 is based on 45,541,358 shares of Common Stock outstanding as of September 30, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2026, filed with the Securities and Exchange Commission on November 5, 2026, after giving effect to the 1-for-7 reverse stock split and the merger effected on September 8, 2026, as reported in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 11, 2026.


SCHEDULE 13G



 
ADAR1 Capital Management, LLC
 
Signature:/s/ Daniel Schneeberger
Name/Title:Daniel Schneeberger, Manager
Date:11/16/2026
 
Daniel Schneeberger
 
Signature:/s/ Daniel Schneeberger
Name/Title:Daniel Schneeberger, in his individual capacity
Date:11/16/2026